Therapeutic INR Target for DVT on Warfarin
For patients with deep vein thrombosis (DVT) treated with warfarin (Coumadin), the therapeutic INR target is 2.5 with a range of 2.0-3.0.
Evidence Basis
This recommendation is consistently supported across multiple high-quality guidelines and the FDA drug label:
The FDA-approved Coumadin label explicitly states: "Adjust the warfarin dose to maintain a target INR of 2.5 (INR range, 2.0-3.0) for all treatment durations" for venous thromboembolism including DVT 1.
The 2024 CHEST guidelines (most recent comprehensive VTE guidance) strongly recommend "a therapeutic INR range of 2.0 to 3.0 (target INR, 2.5) over a lower (INR < 2) or higher (INR 3.0-5.0) range for all treatment durations" 2.
The 2020 American Society of Hematology guidelines provide a strong recommendation for "use of an international normalized ratio (INR) range of 2.0 to 3.0 over a lower INR range for patients with VTE who use a vitamin K antagonist (VKA)" 3.
The 2012 ACCP guidelines (9th edition) similarly recommend "a therapeutic INR range of 2.0 to 3.0 (target INR of 2.5) over a lower (INR < 2) or higher (INR 3.0-5.0) range for all treatment durations" 4.
Clinical Rationale
Why not lower (INR <2.0)? Subtherapeutic anticoagulation dramatically increases thrombotic risk. Research demonstrates that patients with INR <2.0 have a 3.37-fold increased risk of recurrent VTE compared to therapeutic range 5. The risk of thrombosis with low INR far exceeds bleeding risk with therapeutic INR 6.
Why not higher (INR 3.0-5.0)? An INR greater than 4.0 provides no additional therapeutic benefit and significantly increases bleeding risk 1. The higher INR range (2.5-3.5) is reserved specifically for mechanical heart valves in certain positions, not for DVT 2, 1.
Monitoring Requirements
- Initial phase: Check INR daily until stable, then 2-3 times weekly for 1-2 weeks 7
- Maintenance phase: Weekly for 1 month, then every 1-2 months if stable 7
- Overlap with parenteral anticoagulation: Continue heparin/LMWH for minimum 5 days AND until INR ≥2.0 for at least 24 hours 2, 8, 1
Common Pitfalls
Time in therapeutic range (TTR) matters critically. Patients should maintain INR 2.0-3.0 for at least 45-50% of the time, ideally >60-75% 6. Poor INR control (TTR <50%) indicates inadequate anticoagulation and warrants either improved monitoring, patient education, or consideration of switching to a direct oral anticoagulant 6.
INR variability increases at higher targets. Research shows that TTR decreases as the target INR range increases above 2.0-3.0, making higher ranges both less effective and more difficult to manage 9.
Subtherapeutic INR is more dangerous than supratherapeutic. The case-fatality rate of recurrent VTE (5%) in undertreated patients approaches that of major bleeding (9%) from overanticoagulation, but recurrent thrombosis occurs far more frequently with low INR 6.